

Annex 1. EUCAST clinical breakpoints and epidemiological cut-off values for the priority list of antimicrobials to be tested for *Salmonella enterica* as of 31 August 2021

Antimicrobial	Criteria based on MIC dilution (mg/L)			Recommended concentration range ¹ (mg/L) (number of wells)	Criteria based on disk diffusion (mm)			Disk load (µg)
	S≤	R>	NWT>		S≥	R<	NWT<	
First priority								
Ampicillin (AMP)	8.0	8.0	4.0	1-32 (6)	14	14	18	10
Azithromycin (AZM)	ND	ND	16	2-64 (6)	ND	ND	12	15
Cefotaxime (CTX)	1.0	2.0 (1.0) ²	0.5	0.25-4 (5), 0.25-64 (9) ³	20	17 (21) ²	20	5
Ceftazidime (CAZ)	1.0 ²	4.0 (1.0) ²	2.0	0.25-8 (6), 0.25-128 (10) ³	22 ³	19	20	10
Chloramphenicol (CHL)	8.0	8.0	16.0	8-64 (4)	17	17	19	30
Ciprofloxacin (CIP)	0.06	0.06	0.064	0.015-8 (10)	NA	NA	NA	NA
Colistin (COL)	2.0	2.0	NA	1-16 (5)	NA	NA	NA	NA
Gentamicin (GEN)	2.0	2.0	2.0	0.5-16 (6)	17	17	17	10
Meropenem (MEM)	2.0	8.0	0.06 (0.125) ²	0.03-16 (10)	22	16	27 (28) ²	10
Pefloxacin	NA	NA	NA	NA	24	24	24	5
Sulfamethoxazole (SMX)	ND	ND	ND	8-512 (7)	ND	ND	ND	100
Tetracycline (TCY)	ND	ND	8.0	2-32 (5)	ND	ND	17	30
Tigecycline (TGC)	ND	ND	ND	0.25-8 (6)	ND	ND	16	15
Trimethoprim (TMP)	4.0	4.0	2.0	0.25-16 (7)	15	15	23	5
Second level testing ESBL-producers								
Cefepime (FEP)	1.0	4.0	ND		27	24	ND	30
Cefoxitin (FOX)	ND	ND	8.0 ²	0.5-64 (8)	19	19 ²	21	30
Optional								
Amoxicillin (AMX)	8.0	8.0	4.0		ND	ND	ND	10
Ceftriaxone (CRO)	1.0	2.0 (1.0) ²	0.25		25	22 (23) ²	ND	30
Ertapenem (ETP)	0.5	0.5	ND (0.125) ²	0.015-2 (8)	25	25 ³	ND	10
Nalidixic acid (NAL)	ND	ND	8.0	4-64 (5)	ND	ND	16	30
Trimethoprim-sulfamethoxazole (SXT)	2.0	4.0	ND		14	11	22	1.25-23.75

S – clinically susceptible, standard dosing regimen; R – clinically resistant; NWT – non-wild type according to epidemiological cut-off; ND – not determined; NA – not applicable as test method unsuitable for this antimicrobial

1. From Commission Implementing Decision (EU) 2020/1729 on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria and repealing Implementing Decision 2013/652/EU

2. Please note that these interpretive criteria should be used when screening for ESBL-production or carbapenemase-production, according to EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance

3. Test wider range if first test indicates resistance/non-wild type with the screening breakpoint

Annex 2. EUCAST clinical breakpoints and epidemiological cut-off values for the priority list of antimicrobials to be tested for *Campylobacter jejuni* and *C. coli* as of 31 August 2021

Antimicrobial	Criteria based on MIC dilution (mg/L)			Recommended concentration range ¹ (mg/L) (number of wells)	Criteria based on disk diffusion (mm)			Disk load (µg)
	S≤	R>	NWT >		S≥	R<	NWT<	
First priority								
Ciprofloxacin (CIP)	0.001	0.5	0.5	0.12-32 (9)	50	26	26	5
Erythromycin (ERY) <i>C. jejuni</i>	4.0	4.0	4.0	1-512 (10)	20	20	22	15
Erythromycin (ERY) <i>C. coli</i>	8.0	8.0	8.0	1-512 (10)	24	24	24	15
Gentamicin (GEN)	ND	ND	1.0	0.25-16 (7)	ND	ND	20	10
Tetracycline (TCY) <i>C. jejuni</i>	2.0	2.0	1.0	0.5-64 (8)	30	30	30	30
Tetracycline (TCY) <i>C. coli</i>	2.0	2.0	2.0	0.5-64 (8)	30	30	30	30
Optional								
Amoxicillin + clavulanic acid (AMC)	ND	ND	ND		ND	ND	ND	30
Azithromycin (AZM) <i>C. jejuni</i>	ND	ND	0.25		ND	ND	ND	
Azithromycin (AZM) <i>C. coli</i>	ND	ND	0.5		ND	ND	ND	
Ertapenem (ETP)	ND	ND	ND	0.125-4 (6) ¹	ND	ND	ND	
Imipenem (IMP)	ND	ND	ND		ND	ND	ND	
Meropenem (MEM)	ND	ND	ND		ND	ND	ND	10

S – clinically susceptible, standard dosing regimen; R – clinically resistant; NWT – non-wild type according to epidemiological cut-off; ND – not determined

1. From the Commission Implementing Decision (EU) 2020/1729 on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria and repealing Implementing Decision 2013/652/EU